SCHEMBL5693569

SCHEMBL5693569

OCCCc1nc2ccccc2o1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.72
NPC1 O15118 3/20 0.72
RAB9A P51151 3/20 0.72
LOXL2 Q9Y4K0 1/20 0.64
SMN1; SMN2 Q16637 3/20 0.56
TP53 P04637 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.55
GFER P55789 1/20 0.55
DRD3 P35462 7/20 0.52
DRD2 P14416 5/20 0.52
DRD4 P21917 3/20 0.52
DRD1 P21728 2/20 0.48
HTR1A P08908 1/20 0.46
HTR2A P28223 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5703655 0.95 MAPT (0.70) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL6206772 0.93 NPC1 (0.68) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL2123399 0.89 MAPT (0.78) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL31276791 0.89 MAPT (0.78) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL9642061 0.89 MAPT (0.84) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL11399187 0.89 MAPT (0.84) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL155002 0.85 MAPT (1.00) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL2986628 0.82 NPC1 (0.72) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL22871601 0.82 MAPT (0.72) MAPTNPC1RAB9ALOXL2SMN1; SMN2
SCHEMBL4280291 0.82 MAPT (0.72) MAPTNPC1RAB9ALOXL2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664003-A1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2006-06-07 EP disclosed
EP-1495007-A4 PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES AXYS PHARM INC (US) 2006-05-03 EP disclosed
WO-2005028454-A1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed
EP-1495007-A1 PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES AXYS PHARMACEUTICALS, INC. (US) 2005-01-12 EP disclosed
WO-2003087068-A1 PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES AXYS PHARMACEUTICALS, INC. (US) 2003-10-23 WO disclosed
US-H1893-H REACTING A HALOKETONE COMPOUND OR SALT WITH AN OXIDOREDUCTASE ENZYME SUPPLYING MICROORGANISM OR OXIDOREDUCTASE ENZYME CONTAINING MATERIAL OBTAINED FROM THE MICROORGANISM, CATALYZES THE REDUCTION OF HALOKETONE TO FORM HALOHYDROXIDES BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-03 US disclosed
US-5776933-A Method of inhibiting protease E. R. SQUIBB & SONS, INC. (US) 1998-07-07 US disclosed
US-5760036-A ENZYME INHIBITORS OF RETROVIRAL PROTEASE FOR PREVENTION OF AIDS E. R. SQUIBB & SONS, INC. (US) 1998-06-02 US disclosed
US-5559256-A Aminediol protease inhibitors E. R. SQUIBB & SONS, INC. (US) 1996-09-24 US disclosed
EP-0580402-A2 Aminediol protease inhibitors E.R. SQUIBB & SONS, INC. (US) 1994-01-26 EP disclosed